Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Cash ratio

Cash ratio at other companies

Alkermes logo
AlkermesALKS
0.6×-0.3×
JAN
Janus Living JAN
0.3×0.0×

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

cash and equivalents/total current liabilities=0.2×

Based on the most recent quarter.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's cash ratio?
Indivior Pharmaceuticals, Inc. (INDV) reported cash ratio of 0.2× in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's cash ratio changed year-over-year?
Indivior Pharmaceuticals, Inc. 's cash ratio decreased by 39.3% year-over-year, from 0.4× to 0.2×.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's cash ratio?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's cash ratio has grown at a -7.0% compound annual growth rate (CAGR), from 0.2× to 0.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.